Join Prescience for lunch to hear from David Kirn, a global leader in the clinical research and development of oncolytic viruses for cancer. Kirn will talk about Jennerex Biotherapeutics, one of the Bay Area’s most promising clinical-stage biotherapeutics companies. Jennerex’s lead product is currently in a Phase 2b clinical trial for hepatocellular carcinoma and Phase 1/2 clinical development for colorectal cancer. Kirn will share insights into the science on which Jennerex is based, tips for founding a successful start-up, and his vision for the future of the life sciences. More information and online registration is here.